Phospholipase Cbeta 1b, a target to limit atrial dilatation

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1002328

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We have identified a heart specific protein that is involved in perpetuating dilatation of the upper chambers of the heart and thereby contributing to cardiac disease. Inhibitors of this protein provide a suitable target for therapy to limit heart disease. The current studies aim to test such inhibitors in vivo as proof-of-concept that such treatment effectively limits cardiac dysfunction.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $544,847.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cardiology (incl. Cardiovascular Diseases)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

atrial fibrillation | cardiac dysfunction | receptor signalling | signalling pathways | valve regurgitation

Related Links